A nationwide study of metabolic syndrome prevalence in Iran; a comparative analysis of six definitions.
<h4>Introduction</h4>To integrate and execute a proper preventive plan and reduce the risk of non-communicable diseases (NCDs), policy makers need to have access to both reliable data and a unique definition of metabolic syndrome (MetS). This study was conducted on the data collected by...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0241926 |
id |
doaj-39311ed707884eb1b6cf6f67fcf915d6 |
---|---|
record_format |
Article |
spelling |
doaj-39311ed707884eb1b6cf6f67fcf915d62021-03-14T05:32:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01163e024192610.1371/journal.pone.0241926A nationwide study of metabolic syndrome prevalence in Iran; a comparative analysis of six definitions.Ozra Tabatabaei-MalazySahar Saeedi MoghaddamNazila RezaeiAli SheidaeiMohammad Javad HajipourNegar MahmoudiZohreh MahmoudiArezou Dilmaghani-MarandKamyar RezaeeMahdi SabooniFarideh RaziFarzad KompaniAlireza DelavariBagher LarijaniFarshad Farzadfar<h4>Introduction</h4>To integrate and execute a proper preventive plan and reduce the risk of non-communicable diseases (NCDs), policy makers need to have access to both reliable data and a unique definition of metabolic syndrome (MetS). This study was conducted on the data collected by cross-sectional studies of WHO's STEPwise approach to surveillance of NCD risk factors (STEPs) to estimate the national and sub-national prevalence rates of MetS in Iran in 2016.<h4>Materials and methods</h4>The prevalence of MetS was estimated among 18,414 individuals aged ≥25 years living in urban and rural areas of Iran using various definition criteria; National Cholesterol Education Program Adult Treatment Panel III 2004 (ATP III), International Diabetes Federation (IDF), American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI), Joint Interim Statement (JIS). Regional IDF (RIDF) and JIS (RJIS) were defined using ethnicity-specific values of waist circumference for the country.<h4>Results</h4>National prevalence rate of MetS based on ATP III, IDF, AHA/NHLBI, JIS, RIDF and RJIS criteria were 38.3% (95% CI 37.4-39.1), 43.5% (42.7-44.4), 40.9% (40.1-41.8), 47.6% (46.8-48.5), 32.0% (31.2-32.9), and 40.8% (40.0-41.7), respectively. The prevalence was higher among females, in urban residents, and those aged 65-69 years. MetS was expected to affect about 18.7, 21.3, 20.0, 23.3, 15.7, and 20.0 million Iranians, respectively, based on ATP III, IDF, AHA/NHLBI, JIS, RIDF and RJIS. The two most common components noted in this population were reduced high-density lipoprotein cholesterol (HDL-C) levels and central obesity.<h4>Conclusion</h4>High prevalence rate of MetS among Iranian adults is alarming, especially among females, urban residents, and the elderly. The JIS definition criteria is more appropriate to determine higher number of Iranians at risk of NCDs. Proper management and prevention of MetS is required to adopt multiple national plans including lifestyle modifications, medical interventions, and public education on NCDs risk factors.https://doi.org/10.1371/journal.pone.0241926 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ozra Tabatabaei-Malazy Sahar Saeedi Moghaddam Nazila Rezaei Ali Sheidaei Mohammad Javad Hajipour Negar Mahmoudi Zohreh Mahmoudi Arezou Dilmaghani-Marand Kamyar Rezaee Mahdi Sabooni Farideh Razi Farzad Kompani Alireza Delavari Bagher Larijani Farshad Farzadfar |
spellingShingle |
Ozra Tabatabaei-Malazy Sahar Saeedi Moghaddam Nazila Rezaei Ali Sheidaei Mohammad Javad Hajipour Negar Mahmoudi Zohreh Mahmoudi Arezou Dilmaghani-Marand Kamyar Rezaee Mahdi Sabooni Farideh Razi Farzad Kompani Alireza Delavari Bagher Larijani Farshad Farzadfar A nationwide study of metabolic syndrome prevalence in Iran; a comparative analysis of six definitions. PLoS ONE |
author_facet |
Ozra Tabatabaei-Malazy Sahar Saeedi Moghaddam Nazila Rezaei Ali Sheidaei Mohammad Javad Hajipour Negar Mahmoudi Zohreh Mahmoudi Arezou Dilmaghani-Marand Kamyar Rezaee Mahdi Sabooni Farideh Razi Farzad Kompani Alireza Delavari Bagher Larijani Farshad Farzadfar |
author_sort |
Ozra Tabatabaei-Malazy |
title |
A nationwide study of metabolic syndrome prevalence in Iran; a comparative analysis of six definitions. |
title_short |
A nationwide study of metabolic syndrome prevalence in Iran; a comparative analysis of six definitions. |
title_full |
A nationwide study of metabolic syndrome prevalence in Iran; a comparative analysis of six definitions. |
title_fullStr |
A nationwide study of metabolic syndrome prevalence in Iran; a comparative analysis of six definitions. |
title_full_unstemmed |
A nationwide study of metabolic syndrome prevalence in Iran; a comparative analysis of six definitions. |
title_sort |
nationwide study of metabolic syndrome prevalence in iran; a comparative analysis of six definitions. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2021-01-01 |
description |
<h4>Introduction</h4>To integrate and execute a proper preventive plan and reduce the risk of non-communicable diseases (NCDs), policy makers need to have access to both reliable data and a unique definition of metabolic syndrome (MetS). This study was conducted on the data collected by cross-sectional studies of WHO's STEPwise approach to surveillance of NCD risk factors (STEPs) to estimate the national and sub-national prevalence rates of MetS in Iran in 2016.<h4>Materials and methods</h4>The prevalence of MetS was estimated among 18,414 individuals aged ≥25 years living in urban and rural areas of Iran using various definition criteria; National Cholesterol Education Program Adult Treatment Panel III 2004 (ATP III), International Diabetes Federation (IDF), American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI), Joint Interim Statement (JIS). Regional IDF (RIDF) and JIS (RJIS) were defined using ethnicity-specific values of waist circumference for the country.<h4>Results</h4>National prevalence rate of MetS based on ATP III, IDF, AHA/NHLBI, JIS, RIDF and RJIS criteria were 38.3% (95% CI 37.4-39.1), 43.5% (42.7-44.4), 40.9% (40.1-41.8), 47.6% (46.8-48.5), 32.0% (31.2-32.9), and 40.8% (40.0-41.7), respectively. The prevalence was higher among females, in urban residents, and those aged 65-69 years. MetS was expected to affect about 18.7, 21.3, 20.0, 23.3, 15.7, and 20.0 million Iranians, respectively, based on ATP III, IDF, AHA/NHLBI, JIS, RIDF and RJIS. The two most common components noted in this population were reduced high-density lipoprotein cholesterol (HDL-C) levels and central obesity.<h4>Conclusion</h4>High prevalence rate of MetS among Iranian adults is alarming, especially among females, urban residents, and the elderly. The JIS definition criteria is more appropriate to determine higher number of Iranians at risk of NCDs. Proper management and prevention of MetS is required to adopt multiple national plans including lifestyle modifications, medical interventions, and public education on NCDs risk factors. |
url |
https://doi.org/10.1371/journal.pone.0241926 |
work_keys_str_mv |
AT ozratabatabaeimalazy anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT saharsaeedimoghaddam anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT nazilarezaei anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT alisheidaei anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT mohammadjavadhajipour anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT negarmahmoudi anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT zohrehmahmoudi anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT arezoudilmaghanimarand anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT kamyarrezaee anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT mahdisabooni anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT faridehrazi anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT farzadkompani anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT alirezadelavari anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT bagherlarijani anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT farshadfarzadfar anationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT ozratabatabaeimalazy nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT saharsaeedimoghaddam nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT nazilarezaei nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT alisheidaei nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT mohammadjavadhajipour nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT negarmahmoudi nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT zohrehmahmoudi nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT arezoudilmaghanimarand nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT kamyarrezaee nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT mahdisabooni nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT faridehrazi nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT farzadkompani nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT alirezadelavari nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT bagherlarijani nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions AT farshadfarzadfar nationwidestudyofmetabolicsyndromeprevalenceiniranacomparativeanalysisofsixdefinitions |
_version_ |
1714785801880993792 |